Bio Plus Co

Bio Plus Co FCF Growth

The Year-over-Year Free Cash Flow Growth of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 55.36 %. In the previous year, Year-over-Year Free Cash Flow Growth was -1,244.21 % — a change of -104.45% (higher).

FCF Growth

55.36 %

YoY

-104.45%

Last updated:

Year-over-Year Free Cash Flow Growth of Bio Plus Co is 2025 55.36 % . Year-over-Year Free Cash Flow Growth of Bio Plus Co was 2024 -1,244.21 % . It decreases by -104.45% higher compared to the previous year.

The Bio Plus Co FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
-164.28 KRW
Jan 1, 2020
676.84 KRW
Jan 1, 2021
-122.41 KRW
Jan 1, 2022
432.38 KRW
Jan 1, 2023
-182.99 KRW
Jan 1, 2024
-1,244.21 KRW
Jan 1, 2025
55.36 KRW
The Bio Plus Co FCF Growth history
YEARFCF GrowthYoY
55.36 %-104.45%
-1,244.21 %+579.92%
-182.99 %-142.32%
432.38 %-453.21%
-122.41 %-118.09%
676.84 %-512.01%
-164.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Year-over-Year Free Cash Flow Growth of Bio Plus Co is 55.36 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Bio Plus Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Bio Plus Co

All Key Metrics — Bio Plus Co